WRN helicase is a synthetic lethal target in microsatellite unstable cancers.

Saved in:
Bibliographic Details
Title: WRN helicase is a synthetic lethal target in microsatellite unstable cancers.
Authors: Chan EM; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Shibue T; Broad Institute of Harvard and MIT, Cambridge, MA, USA., McFarland JM; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Gaeta B; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Ghandi M; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Dumont N; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Gonzalez A; Broad Institute of Harvard and MIT, Cambridge, MA, USA., McPartlan JS; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Li T; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Zhang Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Bin Liu J; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Lazaro JB; Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Gu P; Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, USA., Piett CG; Department of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, MA, USA., Apffel A; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Ali SO; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Deasy R; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Keskula P; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Ng RWS; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Roberts EA; Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Reznichenko E; Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Leung L; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Alimova M; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Schenone M; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Islam M; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Maruvka YE; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Liu Y; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Roper J; Department of Medicine, Division of Gastroenterology, Duke University, Durham, NC, USA., Raghavan S; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Giannakis M; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Tseng YY; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Nagel ZD; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, MA, USA., D'Andrea A; Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Root DE; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Boehm JS; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Getz G; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Chang S; Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, USA.; Department of Pathology, Yale University School of Medicine, New Haven, CT, USA.; Department of Molecular Biophysics and Biochemistry, Yale University School of Medicine, New Haven, CT, USA., Golub TR; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Howard Hughes Medical Institute, Chevy Chase, MD, USA., Tsherniak A; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Vazquez F; Broad Institute of Harvard and MIT, Cambridge, MA, USA. vazquez@broadinstitute.org.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. vazquez@broadinstitute.org., Bass AJ; Broad Institute of Harvard and MIT, Cambridge, MA, USA. adam_bass@dfci.harvard.edu.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. adam_bass@dfci.harvard.edu.
Source: Nature [Nature] 2019 Apr; Vol. 568 (7753), pp. 551-556. Date of Electronic Publication: 2019 Apr 10.
Publication Type: Journal Article
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 0410462 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-4687 (Electronic) Linking ISSN: 00280836 NLM ISO Abbreviation: Nature Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1476-4687
DOI:10.1038/s41586-019-1102-x